{
  "docId": "019dd923-5fec-763b-95ce-df36eb136cb7",
  "docSlug": "v2M0U9ih51yxmXlSsD1M",
  "documentTitle": "See the pitch deck a psychedelics startup just used to raise $18.6 million to develop new treatments derived from the Sonoran Desert toad",
  "authorId": "Pitchdecks",
  "authorName": "Beckley Psytech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 10,
  "pageCount": 22,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "timeline",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 5,
  "notes": "The slide uses a hexagonal honeycomb-style timeline layout.",
  "elementsJson": [
    "timeline_visual",
    "headline_text"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95ce-df36eb136cb7/10",
  "deckHref": "/decks/019dd923-5fec-763b-95ce-df36eb136cb7",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95ce-df36eb136cb7.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95ce-df36eb136cb7#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.29
      },
      "kind": "framework",
      "text": "2005: Alcohol Addiction, Ayahuasca, Significant reduction in alcohol use. 2014: Tobacco Addiction, Psilocybin, 80% of patients smoke free. 2015: Depression, Ayahuasca, 82% reduction in depression scales. 2016: Treatment-Resistant Depression, Psilocybin, 63% remission rates. 2016: Existential Distress, Psilocybin, 80% response rate. Ongoing: Cluster Headache & Migraine, Psilocybin.",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7969194d-90b2-4dab-bb44-ea578adf4871",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.21,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Psychedelics: A new class of neuropsychiatric treatment with blockbuster potential, but further pharmaceutical development is needed",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95948727-e4d1-4e3b-9c00-cb22f09f1cbe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "f2177757-55fc-47ff-8105-62a6b4a560e9",
      "evidence": "Chronological sequence of clinical research events.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "73496664-182b-4790-bfd4-11bd301d81a0",
      "evidence": "The deck highlights macroeconomic drivers and the current opportunity on pages 9-11",
      "position": 0,
      "objective": "Why now is the right time for psychedelic drug development",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.7,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}